本帖最后由 老马 于 2013-3-13 13:43 编辑
" |! u# O" G, x7 T4 e2 v! N2 ?3 `3 E( w5 I4 g( o, S
健择(吉西他滨)+顺铂+阿瓦斯汀
4 i/ X* K# G$ \ v4 e Gemzar +Cisplatin + Avastin" b1 ^/ ~) a( \. V& y+ K
http://annonc.oxfordjournals.org/content/21/9/1804.full) R% q' X: k b K- A
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 7 K4 P2 s b. v1 Z9 i1 D. ~& ?
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ' V. Q+ g# U- _) p) t
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. / E m4 t( J5 t6 C, p" W. C$ D
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 627)
5 j6 o% h2 S! U9 B
华为网盘附件:. S% r! A2 d4 S# c+ @
【华为网盘】ava.JPG
9 [7 B1 A6 R! g: u" U0 } |